CK7和CK19蛋白在原发性肝癌中的表达和意义

doi:10.3969/j.issn.1004-616x.2026.02.008

摘要/Abstract

摘要： 目的： 探讨细胞角蛋白7（CK7）和CK19在原发性肝癌中的表达，并分析其临床意义。方法： 采用免疫组织化学Envision法检测56例肝癌患者癌组织中细胞角蛋白的表达；采用Spearman相关计算细胞角蛋白之间的相关系数；采用卡方检验或Fisher确切概率法分析CK7和CK19蛋白的表达与患者临床病理指标的关系；采用ROC曲线分析CK7和CK19蛋白表达水平对患者生存状态的预测准确度；采用Kaplan-Meier法计算患者生存率并进行Log-rank法检验。结果： 肝癌组织中CK7、CK8、CK18、CK19、CK20蛋白的阳性表达率分别为30.36%、89.29%、69.64%、21.43%、5.36%;CK7和CK19蛋白的表达水平呈正相关（r=0.602,P=0.00）；在原发性肝癌中，CK7蛋白的表达与肝癌组织的分化程度、病理类型有关（χ²分别为8.155、12.118，均为P<0.05）;CK19蛋白的表达与患者的肿瘤直径、组织分化程度、肿瘤分期、病理类型有关（χ²分别为7.263、15.955、7.292、10.672，均为P<0.05）；预后分析显示，CK7蛋白对患者生存状态预测准确度的受试者工作曲线（ROC）下面积为0.750，标准误为0.210，其95%CI（0.338,1.000）;CK19蛋白的ROC曲线下面积为0.875，标准误为0.155，其95%CI（0.571,1.000）;CK8、CK18、CK20对患者生存状态预测准确度较低；生存分析结果显示，CK7和CK19蛋白对患者生存时间无明显影响（P>0.05）。结论： CK7和CK19蛋白的表达呈正相关；CK7和CK19蛋白均对肝癌患者的组织分化和病理类型有影响；预后分析显示CK7和CK19蛋白的表达能较好预判患者术后生存状态；但生存分析显示二者对患者术后生存时间无明显影响。

关键词: 癌, 原发性肝癌, 细胞角蛋白, 肝癌预后

Abstract: OBJECTIVE: To investigate expressions of cytokeratin 7（CK7） and cytokeratin 19（CK19） in primary liver cancer and to analyze their clinical significance. METHODS: Immunohistochemical Envision method was used to detect expression of cytokeratins in cancer tissues from 56 liver cancer patients. Spearman correlation was used to calculate the correlation coefficient between cytokeratins. The chi-square test or Fisher's exact probability test was used to analyze relationships between expression of CK7 and CK19 proteins and clinicopathological characteristics of patients. ROC curve was used to analyze accuracy of CK7 and CK19 protein expression levels in predicting the survival status of patients. Kaplan-Meier method was used to calculate survival rates of patients,and the Log-rank test was performed. RESULTS: The positive expression rates of CK7, CK8, CK18, CK19, and CK20 proteins in liver cancer tissues were 30.36%, 89.29%,69.64%,21.43%,and 5.36%,respectively. The expression levels of CK7 and CK19 proteins were positively correlated（r=0.602,P=0.00）. In primary liver cancer, expression of CK7 protein was related to the degree of differentiation and pathological type of liver cancer tissue（χ²=8.155,12.118,respectively,P<0.05）. Expression of CK19 protein was related to tumor diameter,tissue differentiation,tumor stage,and pathological type（χ²=7.263,15.955,7.292,10.672,respectively,all P<0.05）. Prognostic analysis showed that the area under the receiver operating characteristic（ROC） curve for CK7 protein in predicting the survival status of patients was0.750,with a standard error of 0.210 and a 95% confidence interval of（0.338,1.000）. The area under the ROC curve for CK19 was 0.875,with a standard error of 0.155 and a 95% confidence interval of（0.571,1.000）. CK8, CK18, and CK20 showed low predictive accuracy for patient survival status. Survival analysis results showed that CK7 and CK19 had no significant effect on the survival time of patients（P>0.05）. CONCLUSION: Expressions of CK7 and CK19 were highly and positively correlated. Both CK7 and CK19 affected tissue differentiation and pathological type of liver cancer patients. Prognostic analysis showed that expression of CK7 and CK19 had good prediction on postoperative survival status of patients. However,survival analysis showed that they have no significant effect on postoperative survival time of patients.

Key words: cancer, primary liver cancer, cytokeratin, prognosis of liver cancer

中图分类号:

R730.2

郭飞宇, 胡浩, 景发, 李伟. CK7和CK19蛋白在原发性肝癌中的表达和意义[J]. 癌变·畸变·突变, 2026, 38(2): 137-141.

GUO Feiyu, HU Hao, JING Fa, LI Wei. Significance of CK7 and CK19 expressions in primary liver cancer[J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2026, 38(2): 137-141.

参考文献

[1] WANG M, ZHOU J M, ZHANG L, et al. Surgical treatment of ovarian cancer liver metastasis[J]. Hepatobiliary Surg Nutr,2019, 8(2):129-137.
[2] 刘鑫苗,高红军,康艳,等.胞质多聚腺苷酸结合蛋白4在肝癌中的表达及其功能[J].癌变·畸变·突变, 2025, 37(3):209-214, 220.
[3] WANG W H, SMITS R, HAO H P, et al. Wnt/β-catenin signaling in liver cancers[J]. Cancers, 2019, 11(7):926.
[4] 周旻,杨冬华,汤绍辉,等.肝癌组织细胞角蛋白7、19表达的评估[J].中国病理生理杂志, 2006, 22(10):2064-2065, 2073.
[5] SUKSWAI N, KHOURY J D. Immunohistochemistry innovations for diagnosis and tissue-based biomarker detection[J]. Curr Hematol Malig Rep, 2019, 14(5):368-375.
[6] BADVE S S, FISHER C. AJCC 8(th)edition-a step forward[J].Breast J, 2020, 26(7):1263-1264.
[7] 朱文标,闫春梅,丘波,等.分泌型卷曲相关蛋白4在肝细胞癌中的表达及其与患者临床病理指标和预后的关系[J].癌变·畸变·突变, 2024, 36(4):288-293, 297.
[8] ZHUO J Y, LU D, TAN W Y, et al. CK19-positive hepatocellular carcinoma is a characteristic subtype[J]. J Cancer, 2020, 11(17):5069-5077.
[9] PARK J H, KIM J H. Pathologic differential diagnosis of metastatic carcinoma in the liver[J]. Clin Mol Hepatol, 2019, 25(1):12-20.
[10] NG K L, ELLIS R J, SAMARATUNGA H, et al. Utility of cytokeratin 7, S100A1 and caveolin-1 as immunohistochemical biomarkers to differentiate chromophobe renal cell carcinoma from renal oncocytoma[J]. Transl Androl Urol, 2019, 8(Sup 2):123-137.
[11] MEHRPOUYA M, POURHASHEM Z, YARDEHNAVI N, et al. Evaluation of cytokeratin 19 as a prognostic tumoral and metastatic marker with focus on improved detection methods[J].J Cell Physiol, 2019, 234(12):21425-21435.
[12] MORALES S, VELASCO A, GASOL A, et al. Circulating tumor cells(CTCs)and cytokeratin 19(CK19)mRNA as prognostic factors in heavily pretreated patients with metastatic breast cancer[J]. Cancer Treat Res Commun, 2018, 16:13-17.
[13] OZSEN M, ADIM S B, AKYILDIZ E U, et al. The role of immunohistochemical staining with CK7 in the differential diagnosis of autoimmune hepatitis[J]. Bratisl Lek Listy, 2019,120(11):839-842.
[14] YANG Z Y, ZHANG H Y, WANG F, et al. Expression of cytokeratin(CK)7, CK8/18, CK19 and p40 in esophageal squamous cell carcinoma and their correlation with prognosis[J]. Chin J Pathol, 2018, 47(11):834-839.
[15] BONACHO T, RODRIGUES F, LIBERAL J. Immunohistochemistry for diagnosis and prognosis of breast cancer:a review[J]. Biotech Histochem, 2020, 95(2):71-91.
[16] SOETA K, IUCHI K, HISATOMI H, et al. Generation of rat monoclonal antibody for cytokeratin 18 by immunization of three-dimensional-cultured cancer cells[J]. Monoclon Antib Immunodiagn Immunother, 2020, 39(6):199-203.
[17] CHENG Y, QIN K, HUANG N, et al. Cytokeratin 18 regulates the transcription and alternative splicing of apoptotic-related genes and pathways in HeLa cells[J]. Oncol Rep, 2019, 42(1):301-312.
[18] SHANG G G, JIN Y, ZHENG Q, et al. Histology and oncogenic driver alterations of lung adenocarcinoma in Chinese[J]. Am J Cancer Res, 2019, 9(6):1212-1223.